Skip to main content
. 2020 Oct 10;126:104051. doi: 10.1016/j.compbiomed.2020.104051

Fig. 5.

Fig. 5

Consolidated drugs and drug categories by combining the five pathways. (A) Top drugs enriched in at least 3 omics-based analyses. (B) Top drug categories with at least 2 drugs. The X axis represents the number of appearances of the drugs/drug categories combining all of our omics-based analyses.